Upload
donga
View
215
Download
0
Embed Size (px)
Citation preview
Alex Crawley & Brent Jensen, BSPRxFiles Academic Detailing ProgramASA-Annual Scientific Assembly
Saskatoon
Drug Therapy Update
Looking back….SUMMER 2016
3
Outline – New Info on» Guidelines
» Tools
» SPDP & NIHB
» From Industry
» Health Canada warnings
» Trials: Flame, Hope‐3, Leader, Sprint
Disclosure RxFilesRxFiles Academic Detailing Academic Detailing
–– Receives grant from Saskatchewan Health through Receives grant from Saskatchewan Health through Saskatoon Health Region to provide academic Saskatoon Health Region to provide academic detailing in Saskatchewandetailing in Saskatchewan
–– Government funding Government funding –– armarm’’s length s length
–– Receives revenue from sale of book, app, and Receives revenue from sale of book, app, and website subscriptions from outside Saskatchewan website subscriptions from outside Saskatchewan Not for profit, not for lossNot for profit, not for loss
–– No industry fundingNo industry funding
What’s New Updated at:
WWW.RxFiles.ca6
» AHA’16 Update Heart Failure
» AHA’16 DAPT Therapy with CAD
» IAS‐USA’16 Adult HIV
» Canmat’16 Canadian Major Depression
» CCS’16 Canadian Dyslipidemia
» CHEP’16 Hypertension
» See www.RxFiles.ca or RxFiles Plus APPfor updated drug charts. Go tohttp://shirp.usask.ca from Drug Info tab
New Guidelines 2016
7
Tools For Practice
INFO POEMS $85/yrINFO POEMS $85/yr
10
Read by QxMD
Your personalized medical journal
New From theSask Drug Plan Top 10 Prescribed Drugs-SPDP
1. Rosuvastatin2. Atorvastatin ‐over 100,000 people on statins3. Levothyroxine ‐concern with heart & osteoporosis4. Metoprolol ‐consider bisoprolol5. Ramipril6. Amlodipine ‐use lower dose, switch, give HS 7. Rabeprazole ‐aware of rebound hyperacidity8. Venlafaxine ‐less useful for mild depression 9. Amoxicillin ‐? Viral, watchful wait, delayed Rx10. Salbutamol
Where is metformin, hydrochlorothiazide etc….
15
Tecta, generic$17/monthPantoprazole
Jaydess$100/yrLevonorgestrel IUD
Amoxicillin + Clavulanate $23/10day Clavulin, generic
Carvedilol $32/month Coreg, generic
Escitalopram $25/month Cipralex, generic
Fluticasone furoate $52‐94/month Arnuity Ellipta
Ipratropium + Salbutamol ~$42/month Combivent Respimat
New Sask Full FormularyNew Sask EDS & NIHB Prior Approval» NEW INHALERS
» Incruse Ellipta (LAMA)
» Tudorza Genuair (LAMA)
» Seebri Breezhaler (LAMA)
» Spiriva Respimat (LAMA)
» Anoro Ellipta (LAMA/LABA)
» Duaklir Genuair (LAMA/LABA) ‐only SK EDS, not prior approval
» Inspiolto Respimat (LAMA/LABA)
» Ultibro Breezhaler (LAMA/LABA)
» Breo Ellipta (LABA/ICS)
» Onbrez Breezhaler (LABA)
New Sask EDS» Breo Ellipta (fluticasone furoate/vilanterol) –asthma
» Cosentyx (secukinumab) –for plaque psoriasis
» Fibristal (ulpristal) for fibroids
» Inflectra (infliximab) & Xeljanz (tofacitinib) for RA
» Inspra (eplerenone) ‐CHF EF<35%, NYHA II
» Invokana, Jardiance & Komboglyze for diabetes
» Myrbetriq (mirabegron) for urinary incontinence
» Ofev (nintedanib) for idiopathic pulmonary fibrosis
» Zaxine (rifaximin) –for IBS
NIHB
19
Combivent Respimat~$42Ipratropium + Salbutamol
Alendronate $265/yr
$190/yr
Fosamax, genericFosavance, generic
Estradiol $510/yr Climara Pro
Ethinyl estradiol+Norethindrone $295/yr Lolo
Moxifloxacin $28/10 days Avelox, generic
Risedronate $260/yr Actonel, generic
Solifenacin $25 Vesicare, generic
Tolterodine $27 Detrol LA, generic
New NIHB Full Formulary New NIHB Prior Approval» Invokana, Jardiance & Komboglyze for diabetes
» Fosrenol (lanthanum) ‐Phosphate binder
» Inflectra (infliximab) for rheumatoid arthritis BIOSIMILAR
» Latuda (lurasidone) for schizophrenia
» Monurol (fosfomycin) for UTI
» Pennsaid (diclofenac) –topical NSAID
21
New From the Industry
22
Health Canada Approved: non formulary» Brenzys (etanercept)
» Brivlera (brivaracetam) for seizures
» Bydureon (exenatide), Invokamet (canagliflozin & MF), Trulicity (dulaglutide) & Xigduo (dapagliflozin & MF) for diabetes
» Descovy (emtricitabine & tenofovir alafenamine) for HIV ? safer on bone & kidney
» Epclusa (sofosbuvir & velpatasvir) & Sunvepra (asunaprevir) for hepatitis C
23
Health Canada Approved: non formulary» Fetzima (levomilnacipran) for depression
» Invega Trinza (paliperidone) depot q3 months for schizophrenia
» Lunesta (eszopiclone) for sedation
» Natesto ‐nasal testosterone gel
» Praluent (alirocumab) & Repatha (evolocumab)–PCSK9 inhibitors for cholesterol
» Praxbind (idarucizumab) –reversal agent for dabigatran
» Striverdi Respimat (olodaterol) for COPD
» Viberzi (eluxadoline) for IBS‐D
» Zerbaxa (ceftolozane with tazobactam) for infections
24
New Generics with Price Reductions» Azilect (rasagiline)
» Celebrex (celecoxib)
» Inflectra (infliximab)
» Keppra (levetiracetam)
» Lyrica (pregabalin) Nexium (esomeprazole)
» Nasocort (triamcinolone) nasal
» Nasonex (mometasone) nasal
» Sublinox (zolpidem)
» Tecta (pantoprazole)
25
New Pan-Canadian Generic Drug Pricing-18 agents in total (4 new additions)
» Donepezil
» Ezetimibe
» Quetiapine
» ZopiclonePreviously: amlodipine; citalopram, venlafaxine; clopidogrel;
gabapentin; metformin; olanzapine & ramipril.
PPI’s: omeprazole, pantoprazole, rabeprazole; Statins: atorvastatin, rosuvastatin, simvastatin;
26
Products with Price Increase» Aventyl (nortriptyline)
» Anafranil (clomipramine)
» Combivent (Ipratropium + salbutamol) NEBS
27
New OTC» Olex (omeprazole 20mg)
» Nexium 24hr (esomeprazole 20mg)
» Nasocort Aq (triamcinolone)
» Hydrocortisone 1% cream & ointment
» Advil 12hr (ibuprofen 600mg MR)
New From Health Canada» ADHD drugs: suicidal thoughts/behaviours» Atarax (hydroxyzine), domperidone: prolong QT, sudden cardiac death» Avonex (interferon): nephrotic syndrome » Codeine: avoid in kids, respiratory depression/fatal » Donepezil: rhabdomyolysis, neuro malignant syndrome» Flozins (SGLT-2) : diabetic ketoacidosis; acute kidney injury (FDA)» Gluconorm (repaglinide) : Contraindication with Clopidogrel» Lamasil: Contraindication if active or chronic hepatitis» Metoclopramide: EPS in children» Tecfidera (dimethyl fumarate): angioedema, PML» Uloric (febuxostat): Dress skin reaction
» Acetaminophen max daily doses; max 5 days pain, 3 days fever.» Diclofenac lower max of 100mg/day since CV risk with this NSAID» Ibuprofen: heart attack, stroke at high doses (2400mg/d) 30
New From RxFiles
CFP Aug 2016
New from RxFiles» Angina Treatment Chart» Drug Interactions Chart» DAPT/Triple Therapy Chart» Trials: info on RxFiles website
» Empa-Reg (empagliflozin) for diabetes» Flame (Ultibro vs Advair) for COPD» Hope-3 (Crestor &/or Atacand Plus) for CV risk» Leader (liraglutide) for diabetes» Pegasus (ticagrelor) for Post-MI » Sprint (intensive BP control 120 vs 140)
Is a LAMA + LABA Ultibro better than LABA + ICS Advair in COPD? Flame NEJM 2016, n=3362 over 52 wks
Trial Summary» Indacaterol+Glycopyrronium daily Ultibro Breezhaler $98 vs
Salmeterol+Fluticasone twice daily Advair $162/month
» N= 3,362 over 52weeks, 4 week run-in period» ALL (mild, moderate, severe) exacerbations (ARR
0.5, p<0.001), but NOT severe exacerbations» pneumonia (ARR 1.6, NNT=63, p=0.02), influenza (ARR 1.3, NNT=77, p=0.026), & oral candidiasis (ARR 3.0, NNT=34, p<0.001)
» Not reduced mortality, but effective, safer & less costly
In intermediate CV risk patients is it better to give Crestor 10mg/day &/or Atacand Plus 16/12.5mg? Hope-3 NEJM 2016, n=12,705 over 5.6yrs
Hope-3 Lipid Trial Summary» Rosuvastatin 10mg CRESTOR 10mg/day was more effective than
placebo in reducing the LDL from 3.3 to 2.3 mmol/L
- first coprimary outcome (composite of cardiovasculardeath, nonfatal MI, or nonfatal stroke), NNT=91 in 5.6 years, HR = 0.76, 95% CI 0.64 to 0.91
- secondary coprimary outcome (first coprimary outcome+ heart failure, resuscitate cardiac arrest, or revasc),NNT=73, HR=0.75, 95% CI 0.64 to 0.88
» Mortality not reduced» more risk of cataract surgery NNH=143,
muscle pain or weakness NNH=91,DVT/PE NNH=346 / 5.6 years.
Hope-3 Trial Summary» For intermediate CV risk patients:
In patients with intermediate CV risk without CVD, adding rosuvastatin 10mg/d may provide more benefit than adding candesartan+HCTZ.
In subgroup of patients with SBP > 143.5mmHg, adding candesartan 16mg/d + HCTZ 12.5mg/d may be beneficial. But more dizziness, lightheadedness & hypotension.
(BP 138/82 reduced to 134/79 or 128/76)
Does liraglutide (Victoza) reduce cardiovascular outcomes in high CV risk patients with diabetes? NEJM 2016, n=9,340 over 3.8yrs
Leader trial (liraglutide $690/3months)» GLP1-Analogue reduces A1C from 8.7 to 8.3%» N=9,340; high CV risk; many on MF & insulin» 1st occurence of death from CV,
nonfatal MI or stroke NNT=53/3.8yrs» Mortality reduced, but not non-fatal MI/stroke» Acute gallbladder dx NNH=84» D/C due to adverse event NNH=46
»Nausea, vomiting, diarrhea» Lost about 2.3kg & lowered SBP ~1.2 mmHG
Is intensive blood pressure lowering to 120 better than 140? SPRINT NEJM 2016 n=9,361 over 3.3yr
SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. DOI: 10.1056/NEJMoa1511939 (Nov 26, 2015)
Xie X et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review & meta-analysis. Lancet Nov 7, 2015.
Sprint
BP 140/78 to 135/76 or 122/64
Sprint
Open label, terminated early, BP meds required 2.8 vs 1.8
BP 140/78 treated to 135/76 or 122/69
Only 17% of US hypertensives would be represented by the trial partly because NO diabetes, stroke or acute heart failure patients included in this trial
Automated BP in ideal setting (120 equals ? 135 or > )unattended, after 5min rest
More Serious Adverse Events NNH=45-hypotension, syncope, renal injury
More CKD progression
Intensive treatment in SELECT (>15% CV risk) pts: -reduced CV events & all cause mortality NNT=63, but significant serious adverse events occur
46
47
306‐655‐8506
Questions???Interested to discuss